AU2007325123B2 - AZA-indolyl compounds and methods of use - Google Patents

AZA-indolyl compounds and methods of use Download PDF

Info

Publication number
AU2007325123B2
AU2007325123B2 AU2007325123A AU2007325123A AU2007325123B2 AU 2007325123 B2 AU2007325123 B2 AU 2007325123B2 AU 2007325123 A AU2007325123 A AU 2007325123A AU 2007325123 A AU2007325123 A AU 2007325123A AU 2007325123 B2 AU2007325123 B2 AU 2007325123B2
Authority
AU
Australia
Prior art keywords
alkyl
mmol
nhc
cr19r20
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007325123A
Other languages
English (en)
Other versions
AU2007325123A1 (en
Inventor
Liang Bao
Hazel Joan Dyke
Simon Charles Goodacre
Wendy Lee
John Gary Montana
Stephen Price
Mark S. Stanley
Karen Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2007325123A1 publication Critical patent/AU2007325123A1/en
Application granted granted Critical
Publication of AU2007325123B2 publication Critical patent/AU2007325123B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2007325123A 2006-11-30 2007-11-29 AZA-indolyl compounds and methods of use Ceased AU2007325123B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US86805506P 2006-11-30 2006-11-30
US60/868,055 2006-11-30
US91762007P 2007-05-11 2007-05-11
US60/917,620 2007-05-11
US94474307P 2007-06-18 2007-06-18
US60/944,743 2007-06-18
PCT/US2007/085962 WO2008067481A1 (en) 2006-11-30 2007-11-29 Aza-indolyl compounds and methods of use

Publications (2)

Publication Number Publication Date
AU2007325123A1 AU2007325123A1 (en) 2008-06-05
AU2007325123B2 true AU2007325123B2 (en) 2012-12-13

Family

ID=39169665

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007325123A Ceased AU2007325123B2 (en) 2006-11-30 2007-11-29 AZA-indolyl compounds and methods of use

Country Status (14)

Country Link
US (1) US7855216B2 (esLanguage)
EP (1) EP2099796B1 (esLanguage)
JP (1) JP5211063B2 (esLanguage)
AR (1) AR064031A1 (esLanguage)
AT (1) ATE511509T1 (esLanguage)
AU (1) AU2007325123B2 (esLanguage)
CA (1) CA2672327A1 (esLanguage)
CL (1) CL2007003444A1 (esLanguage)
DK (1) DK2099796T3 (esLanguage)
PE (1) PE20081354A1 (esLanguage)
PL (1) PL2099796T3 (esLanguage)
PT (1) PT2099796E (esLanguage)
TW (1) TW200829586A (esLanguage)
WO (1) WO2008067481A1 (esLanguage)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010000409A2 (en) * 2008-07-03 2010-01-07 Bayer Schering Pharma Aktiengesellschaft Compounds and processes for production of radiopharmaceuticals
EP2370568B1 (en) 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
US8637246B2 (en) 2010-02-25 2014-01-28 Dana-Farber Cancer Institute, Inc. BRAF mutations conferring resistance to BRAF inhibitors
BR112012022801B8 (pt) 2010-03-09 2019-10-29 Dana Farber Cancer Inst Inc método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
CA2806332C (en) 2010-07-30 2017-11-14 Oncotherapy Science, Inc. Quinoline derivatives and melk inhibitors containing the same
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
UY34893A (es) 2012-07-10 2014-02-28 Takeda Pharmaceutical Derivados de azaindol
CA2890238A1 (en) 2012-11-02 2014-05-08 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
UA111925C2 (uk) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
WO2015196072A2 (en) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
CA3018406A1 (en) 2016-04-15 2017-10-19 Genentech, Inc. Diagnostic and therapeutic methods for cancer
DK3624795T3 (da) 2017-05-19 2022-05-23 Nflection Therapeutics Inc Kondenserede, heteroaromatiske anilinforbindelser til behandling af hudforstyrrelser
PL3624796T3 (pl) * 2017-05-19 2025-06-30 Nflection Therapeutics, Inc. Związki pirolopirydyno-anilinowe do leczenia zaburzeń skórnych
MX2020002553A (es) 2017-09-08 2020-07-22 Hoffmann La Roche Metodos de diagnostico y terapeuticos para el cancer.
US20210008047A1 (en) 2018-02-13 2021-01-14 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
CN117551073A (zh) 2018-11-20 2024-02-13 恩福莱克逊治疗有限公司 用于治疗皮肤疾病噻吩基苯胺化合物
WO2020106308A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
MA55141A (fr) 2018-11-20 2021-09-29 Nflection Therapeutics Inc Composés cyanoaryl-aniline pour le traitement d'affections de la peau
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
IL312977A (en) 2021-11-23 2024-07-01 Nflection Therapeutics Inc Formulations of pyrrolopyridine-aniline compounds
CA3247162A1 (en) * 2022-01-28 2023-08-03 Insilico Medicine Ip Limited Ectunocleotide pyrophosphatase-phosphodiesterase 1 (ENPP1) inhibitors and their uses
US20250171451A1 (en) * 2022-03-04 2025-05-29 Samjin Pharmaceutical Co., Ltd. Novel heterocyclic compound and pharmaceutical composition comprising same
WO2024033381A1 (en) 2022-08-10 2024-02-15 Vib Vzw Inhibition of tcf4/itf2 in the treatment of cancer
WO2025026383A1 (en) * 2023-08-02 2025-02-06 Insilico Medicine Ip Limited Crytsalline forms of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
KR20250067072A (ko) * 2023-11-07 2025-05-14 보로노이 주식회사 헤테로아릴 유도체 화합물 및 이의 용도
WO2026019990A1 (en) 2024-07-18 2026-01-22 Genentech, Inc. Methods of treating cancer with anti-ccr8/anti-cd3 bispecific antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002051A1 (en) * 2004-06-15 2006-01-05 Schering Corporation Tricyclic compounds and their use as mglur1 antagonists
WO2006100095A1 (de) * 2005-03-24 2006-09-28 Curacyte Discovery Gmbh Substituierte carbonsäureamide, verfahren zu ihrer herstellung und ihre verwendung als tnf-alpha-freisetzungsinhibitoren
WO2007070393A2 (en) * 2005-12-13 2007-06-21 Schering Corporation Mglur1 anatgonists as therapeutic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
AU2003239150A1 (en) * 2002-04-23 2003-11-10 Aventis Pharmaceuticals Inc. 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo
US6929411B2 (en) * 2003-09-03 2005-08-16 Hewlett-Packard Development Company, L.P. Selectable control of raster image processor
GB0412914D0 (en) * 2004-06-10 2004-07-14 Oxagen Ltd Compounds
AR070127A1 (es) * 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002051A1 (en) * 2004-06-15 2006-01-05 Schering Corporation Tricyclic compounds and their use as mglur1 antagonists
WO2006100095A1 (de) * 2005-03-24 2006-09-28 Curacyte Discovery Gmbh Substituierte carbonsäureamide, verfahren zu ihrer herstellung und ihre verwendung als tnf-alpha-freisetzungsinhibitoren
WO2007070393A2 (en) * 2005-12-13 2007-06-21 Schering Corporation Mglur1 anatgonists as therapeutic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KANTH, ET AL. Heterocycles, (2005), 65(6): 1415-1423 *

Also Published As

Publication number Publication date
AU2007325123A1 (en) 2008-06-05
US7855216B2 (en) 2010-12-21
EP2099796B1 (en) 2011-06-01
US20080242655A1 (en) 2008-10-02
PT2099796E (pt) 2011-09-06
ATE511509T1 (de) 2011-06-15
EP2099796A1 (en) 2009-09-16
TW200829586A (en) 2008-07-16
WO2008067481A1 (en) 2008-06-05
JP2010511626A (ja) 2010-04-15
PE20081354A1 (es) 2008-11-14
CL2007003444A1 (es) 2008-06-27
JP5211063B2 (ja) 2013-06-12
HK1135099A1 (en) 2010-05-28
AR064031A1 (es) 2009-03-04
PL2099796T3 (pl) 2011-10-31
CA2672327A1 (en) 2008-06-05
DK2099796T3 (da) 2011-09-05

Similar Documents

Publication Publication Date Title
AU2007325123B2 (en) AZA-indolyl compounds and methods of use
CA2706571C (en) 5-anilinoimidazopyridines and methods of use
AU2007286808B2 (en) Aza-benzofuranyl compounds and methods of use
EP2069359B1 (en) Aza-benzothiophenyl compounds and methods of use
AU2009266956B2 (en) Bicyclic heterocycles as MEK kinase inhibitors
CN101583616B (zh) 氮杂苯并噻吩基化合物及使用方法
ES2366932T3 (es) Compuestos de aza-indolilo y métodos de utilización.
HK1135099B (en) Aza-indolyl compounds and methods of use
HK1147254B (en) 5-anilinoimidazopyridines and methods of use

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ AZA-INDOLYL COMPOUNDS AND METHODS OF USE

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired